Beta-Crosslaps (CTX) (Serum, frozen (s))
| Testcode: | CROSSG |
| Specimens: | 750 µl Serum, frozen (s) |
| Preanalytics/Notes: | Fasting blood sampling in the morning between 7.30 and 8.30am. There is a substantial circadian rhythm, therefore the time of sampling of further control examinations is important. Strict fasting blood sampling is important, the patient is only allowed to drink water (no coffee or tea, no drinks containing sugar) before blood sampling! For long-term analysis, the samples must always be collected under the same conditions as the first sample. After blood sampling, let coagulate for approx. 30 - 45 min., centrifuge, remove serum with a pipette and transfer into a new tube, freeze and dispatch deep-frozen. For this purpose let coagulate after blood sampling, for approx. 30 - 45 min., centrifuge, remove serum with a pipette and transfer into a new tube, freeze and dispatch deep-frozen. At room temperature, the parameter is stable for 8 h in the serum. Patients receiving high doses of biotin (> 5 mg / day) should be sampled at least 8 hours after the last application, as high levels of biotin may interfere with the test system. |
| Method: | ECLIA |
| Dimension: | ng/ml |
| Set-up: | Mon Tue Wed Thu Fri Sat Sun |
| Duration: | 1 day |
| Indication/Significance: |
|
| Interpretation: |
Increased: Elevated more… Increased: Elevated values are indicative of an increased destruction of bone. CTX (Beta-CrossLaps) is considered the most reliable marker for increased destruction of bone (osteoporosis), in particular in postmenopausal women. For a correct assessment, it is urgently required that fasting blood sampling takes place in the morning by 8.30am at the latest because of the substantial circadian rhythm. There are only slight diurnal variations in dialysis patients. Elevated levels of Beta-CrossLaps are indicative of an increased destruction of bone. A check of the vitamin D supply (determination of 25(OH) vitamin D) is recommended in the case of elevated levels. Hyperthyrosis, hyperparathyroidism or glycocorticoid therapy may also cause increased destruction of bone. To monitor an antiresorptive therapy, the Beta-CrossLaps analysis should be combined with the analysis of a bone formation marker (ostasis/bone AP). |
| Further tests: | Markers of bone formation, e.g. ostasis/bone AP |
Reference range / valuation (openclose)
| male | ||
|---|---|---|
|
Males: 24 - <30 Years 0.24 - 1.02 ng/ml 30 - <40 Years 0.23 - 0.94 ng/ml 40 - <50 Years 0.18 - 0.80 ng/ml 50 - <60 Years 0.16 - 0.74 ng/ml 60 - <70 Years 0.13 - 0.75 ng/ml >=70 Years 0.12 - 0.78 ng/ml Dialysis patients (normal bone loss) 0.5 - 2.1 ng/ml No reference values are currently available for ages < 24 years. The reference ranges apply to fasting blood samples (12 hours without food) taken between 7:30 and 8:30 a.m. (daily rhythm). Only minor daily fluctuations are observed in dialysis patients. CTX (beta-crosslaps) is considered the most reliable marker for increased bone resorption (osteoporosis), especially in postmenopausal women. If values are elevated, a vitamin D status check (determination of 25-OH vitamin D) is recommended. Hyperthyroidism, hyperparathyroidism, or glucocorticoid therapy can also cause increased bone resorption. To monitor antiresorptive therapy, beta crosslaps determination should be combined with the determination of a bone formation marker (ostase/bone AP). |
||
| female | ||
|---|---|---|
|
Females: 24 - <30 Years 0.15 - 0.97 ng/ml 30 - <40 Years 0.15 - 0.64 ng/ml 40 - <50 Years 0.13 - 0.67 ng/ml 50 - <60 Years 0.18 - 1.01 ng/ml 60 - <70 Years 0.17 - 0.97 ng/ml >=70 Years 0.15 - 0.86 ng/ml If menopausal status is known. the following age-dependent reference ranges apply: Premenopause (women <60 years): 0.14 - 0.7 ng/ml Postmenopause (women >/= 50 years): 0.18 - 1.0 ng/ml There are no specific reference ranges for postmenopausal women under 50 years of age. In these cases. the above age-dependent reference ranges apply. Dialysis patients (normal bone loss) 0.5 - 2.1 ng/ml No reference values are currently available for ages < 24 years. The reference ranges apply to fasting blood samples (12 hours without food) taken between 7:30 and 8:30 a.m. (daily rhythm). Only minor daily fluctuations are observed in dialysis patients. CTX (beta-crosslaps) is considered the most reliable marker for increased bone resorption (osteoporosis), especially in postmenopausal women. If values are elevated, a vitamin D status check (determination of 25-OH vitamin D) is recommended. Hyperthyroidism, hyperparathyroidism, or glucocorticoid therapy can also cause increased bone resorption. To monitor antiresorptive therapy, beta crosslaps determination should be combined with the determination of a bone formation marker (ostase/bone AP). |
||
| both sex | ||
|---|---|---|
|
Males: 24 - <30 Years 0.24 - 1.02 ng/ml 30 - <40 Years 0.23 - 0.94 ng/ml 40 - <50 Years 0.18 - 0.80 ng/ml 50 - <60 Years 0.16 - 0.74 ng/ml 60 - <70 Years 0.13 - 0.75 ng/ml >=70 Years 0.12 - 0.78 ng/ml Dialysis patients (normal bone loss) 0.5 - 2.1 ng/ml No reference values are currently available for ages < 24 years. The reference ranges apply to fasting blood samples (12 hours without food) taken between 7:30 and 8:30 a.m. (daily rhythm). Only minor daily fluctuations are observed in dialysis patients. CTX (beta-crosslaps) is considered the most reliable marker for increased bone resorption (osteoporosis), especially in postmenopausal women. If values are elevated, a vitamin D status check (determination of 25-OH vitamin D) is recommended. Hyperthyroidism, hyperparathyroidism, or glucocorticoid therapy can also cause increased bone resorption. To monitor antiresorptive therapy, beta crosslaps determination should be combined with the determination of a bone formation marker (ostase/bone AP). |
||
initial letter
Abrechnung GOÄ
Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.